Astellas Showcases Innovation in Oncology at ESMO 2025 Meeting
Astellas Showcases Innovation in Oncology at ESMO 2025 Meeting
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -
- Results from the EV-303 trial in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in an ESMO Presidential Symposium -
TOKYO / -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present ten abstracts from its portfolio and pipeline at the European Society for Medical Oncology (ESMO) congress, showcasing advancements in oncology. Notable data includes findings for PADCEV™ (enfortumab vedotin) combined with pembrolizumab for muscle-invasive bladder cancer (MIBC), highlighted in an ESMO Presidential Symposium. Additionally, Astellas will share key insights into XTANDI™ (enzalutamide) in prostate cancer, along with emerging therapies in other areas.
Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Head of Oncology Development at Astellas states, "Astellas is dedicated to tackling some of the most challenging cancers. The data we present at ESMO illustrate our commitment to translating complex scientific findings into meaningful patient benefits. We are thrilled to unveil groundbreaking new survival metrics in bladder and prostate cancers, signifying transformations that could significantly improve patient care. Furthermore, we are excited to continue our leadership in gastric cancers with our bispecific T cell engager innovations.
Key Highlights from Astellas at ESMO 2025
Astellas will present critical findings such as:
- Phase 3 EV-303 trial data for enfortumab vedotin and pembrolizumab, showcased at the ESMO Presidential Symposium, assessing the combination as neoadjuvant and adjuvant therapy for patients with MIBC not eligible for cisplatin chemotherapy.
- Long-term follow-up results from the EV-302 trial, which examines the efficacy of enfortumab vedotin and pembrolizumab in older patients facing challenging baseline conditions, including advanced urothelial cancer instances.
- Final data from the EMBARK trial evaluating overall survival benefits for enzalutamide, either alone or combined with leuprolide, in high-risk non-metastatic hormone-sensitive prostate cancer patients.
- Initial clinical data for Astellas' novel CLDN18.2-targeted bispecific CD3 T cell engager ASP2138, examined both as a standalone treatment and in conjunction with established therapies.
Astellas Presentations at ESMO Congress 2025
Enfortumab Vedotin Presentations
Presentation Title: Perioperative enfortumab vedotin plus pembrolizumab for muscle-invasive bladder cancer patients who are cisplatin-ineligible: Results from the Phase 3 KEYNOTE-905 study
Presenter: C. Vulsteke
Details: Presidential Symposium 1, Abstract Number: LBA2, Scheduled on October 18, 16:52 - 17:04 CEST.
Exploring New Efficacy
Presentation Title: Enfortumab vedotin and pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer: Insights from an exploratory analysis in older patients and those with comorbidities from EV-302.
Presenter: N. Mar
Details: Poster, Abstract Number: 3073P, Scheduled on October 18, 12:00-12:45 CEST.
Enzalutamide Innovations
Overall Survival Insights
Presentation Title: EMBARK trial outcomes evaluating overall survival in patients with non-metastatic hormone-sensitive prostate cancer.
Presenter: S.J. Freedland
Details: Proffered Paper, Abstract Number: LBA87, Scheduled on October 19, 10:55-11:05 CEST.
Pipeline Advancements
Next-Generation Solutions
Presentation Title: ASP2138 monotherapy for patients with advanced solid tumors (CLDN18.2)+, Phase 1/1b trial.
Presenter: K. Shitara
Details: Poster, Abstract Number: 2137P, Scheduled on October 19, 12:00-12:45 CEST.
Astellas continues its commitment to innovation, improving quality of life and outcomes for patients. Their dedication to rigorous research and development highlights their role as a leader in the oncology space.
About Astellas
Astellas is a global life sciences company committed to transforming innovative science into value for patients. With a focus on oncology, ophthalmology, urology, immunology, and women’s health, Astellas aims to deliver groundbreaking therapies addressing high unmet medical needs.
Frequently Asked Questions
What were the key findings presented by Astellas at ESMO 2025?
Astellas highlighted ten abstracts, including promising data for PADCEV and XTANDI demonstrating significant progress in treating cancer.
How do PADCEV and XTANDI contribute to cancer treatment?
PADCEV helps improve outcomes for muscle-invasive bladder cancer while XTANDI provides effective solutions for non-metastatic hormone-sensitive prostate cancer.
What does the pipeline look like for Astellas?
Astellas is introducing new therapies like ASP2138, targeting advanced solid tumors, emphasizing innovation in cancer treatment.
Who is leading Astellas' Oncology Development?
Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., oversees the oncology development portfolio, driving strategic advancements.
How can I learn more about Astellas' products and research?
Further information about Astellas' offerings and research efforts can be found on their official website.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
